Study of the Prognosis of Patients With Heart Failure With Preserved Ejection Fraction

Completed

• Conditions: Heart Failure With Preserved Ejection Fraction

• Registration Number: NCT05496439
• Lead Sponsor: Chongqing Medical University

Brief Summary

Study of the prognosis of patients with heart failure with preserved ejection fraction

Detailed Description

Obesity is an independent risk factor for heart failure with preserved ejection fraction (HFpEF), however, the impact of visceral fat area (VFA) in patients with HFpEF is unclear. According to established process of patients' selection, a total of 172 patients whose mean age was 72 years were included in this study, and the median follow-up duration was 395.5 days(interquartile range: 207.5 to 535.5 days). All patients were divided into two groups based on the best cut-off value of VFA, and the primary outcome of this study was all-cause death in patients with HFpEF. The aim of this study was to clarify whether VFA has prognostic value in patients with HFpEF by Kaplan-Meier analysis and cox analysis.

Study Timeline

• Study Start: 2020-03-01
• Primary Completion: 2022-05-22
• Study Completion: 2022-07-06
• Status Verified: 2022-08
• Study First Submitted: 2022-08-05
• Study First Submitted QC: 2022-08-10
• Last Update Submitted: 2022-08-10
• Study First Posted: 2022-08-11
• Last Update Posted: 2022-08-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 172

Inclusion Criteria

1. Adult aged >=18years old;
2. Diagnosed with HFpEF.Diagnostic criteria including:

1）left ventricular ejection fraction ≥50%； 2）with the symptoms and/or signs of heart failure； 3）BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL； 4）at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

Exclusion Criteria

1. Age <18 years old；
2. LVEF less than 45% at any time;
3. cancer diagnosis.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
death	The median follow-up time of 395.5 days(interquartile range: 207.5 to 535.5 days)	all-cause death

Trial Locations

Locations (1)

The First Affiliated Hospital of Chongqing Medical University; 🇨🇳 Chongqing, China